Vaxxas adds three expert advisors to provide regulatory and manufacturing advice
Clinical stage biotechnology company Vaxxas, which is commercialising a needle-free vaccine delivery platform, has added three new expert advisors to its product development and strategy team. In a statement on Thursday morning (Australian time), the company said Dr Emilio Emini, Dr Nathalie Garcon, and Professor Paul Young will join Vaxxas as consultants to provide regulatory…